Liquid-Phase Synthesis of Oligonucleotides
This review will summarize recent progress of liquid-phase oligonucleotide synthesis and also briefly introduce the challenge to develop a process that applies our original liquid-phase synthesis technology for practical use.
Recent progress in various types of oligonucleotide therapeutics, such as antisense, aptamer, siRNA and miRNA, has led to growing demand for economical and/or large scale production. Conventionally-known solid-phase synthesis which has been only a method of choice over the past few decades rapidly supplies oligonucleotides in high quality but in a limited quantity. Major issues of solid-phase synthesis that need to be addressed are scale-up and manufacturing cost. The former is attributable to the dedicated synthesizer’s capacity and the latter associate with heterogeneous reactions: use of expensive resins and excess amidite reagents.
Liquid-phase approaches may overcome these limitations. Behind the progress of solid-phase synthesis, researchers have investigated unique liquid-phase approaches. Among them, several methods utilizing soluble supports instead of solid resins are combining the advantage of solid-phase synthesis and liquid-phase synthesis, and expected to have possibility of industry applicable methods.
KeywordsLiquid-phase oligonucleotide synthesis Solution-phase Large scale production Soluble supports Scale-up AJIPHASE®
- 1.Freier SM, Watt AT (2001) Basic principles of antisense drug discovery. In: Crooke ST (ed) Antisense drug technology: principles, strategies, and applications, 2nd edn. Marcel Dekker, New YorkGoogle Scholar
- 2.a) Sharma VK, Sharma RK, Singh SK (2014) Antisense oligonucleotides: modifications and clinical trials. Med Chem Commun 5:1454–1471; b) Sharma VK, Rungta P, Prasad AK (2014) Nucleic acid therapeutics: basic concepts and recent developments. RCS Adv 4:16618–16631Google Scholar
- 4.a) Campbell MA, Wengel J (2011) Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev 40:5680–5689; b) Kaur H, Babu BR, Maiti S (2007) Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA) Chem Rev 107:4672–4697; c) Obika S (2004) Development of bridged nucleic acid analogues for antigene technology. Chem Pharm Bull 52:1399–1404Google Scholar
- 6.a) Geary RS, Baker BF, Crooke ST (2015) Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro®): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet 54:133–146; b) Hair P, Cameron F, McKeage K (2013) Mipomersen sodium: first global approval. Drugs 73:487–493Google Scholar
- 7.Sanghvi YS, Schulte M (2004) Therapeutic oligonucleotides: the state-of-the-art in purification technologies. Curr Opin Drug Discov Devel 6:765–776Google Scholar
- 9.a) Reese CB, Song Q (1997) A new approach to the synthesis of oligonucleotides and their phosphorothioate analogues in solution. Bioorg Med Chem Lett 7:2787–2792; b) Reese CB, Song Q (1999) The H-phosphonate approach to the solution phase synthesis of linear and cyclic oligoribonucleotides. Nucl Acids Res 27:963–971; c) Reese CB, Song Q (1999) The H-phosphonate approach to the synthesis of oligonucleotides and their phosphorothioate analogues in solution. J Chem Soc Perkin Trans 1 1477–1486; d) Reese CB, Yan H (2002) Solution phase synthesis of ISIS 2922 (Vitravene) by the modified H-phosphonate approach. J Chem Soc Perkin Trans 1:2619–2633Google Scholar
- 12.Gimenez A, Kungurtsev V, Virta P et al (2012) Acetylated and methylated β-cyclodextrins as viable soluble supports for the synthesis of short 2′-oligodeoxyribo-nucleotides in solution. Molecules 17:12012–12120Google Scholar
- 13.a) Bonora GM (1987) Gazzetta Chim Ital 117:379–380; b) Bonora GM (1995) Polyethylene glycol. Appl Biochem Biotechnol 54:3–17Google Scholar
- 14.a) Bonora GM, Scremin CL, Colonna FP et al (1990) Nucleic Acids Res 18:3155–3159; b) Colonna FP, Scremin CL, Bonora GM (1991) Large scale H.E.L.P. synthesis of oligodeoxynucleotides by the hydroxybenzotriazole phosphotriester approach. Tetrahedron Lett 32:3251–3254; c) Bonora GM, Scremin CL, Colonna FP et al (1991) Nucleosides Nucleotides 10:269–273Google Scholar
- 17.a) Scremin CL, Bonora GM (1993) Liquid phase synthesis of phosphorothioate oligonucleotides on polyethylene glycol support. Tetrahedron Lett 34:4663–4666; b) Bonora GM, Zaramella S, Ravikumar V (2001) Large-scale solution synthesis of phosphorothioate oligonucleotides: a comparison of the phosphoroamidite and phosphotriester dimeric approaches. Croat Chim Acta 74:779–786Google Scholar
- 19.a) Donga RA, Khaliq-Uz-Zaman SM, Chan TH et al (2006) A novel approach to oligonucleotide synthesis using an imidazolium ion tag as a soluble support. J Org Chem 71:7907–7910; b) Donga RA, Hassler M, Chan TH et al (2007) Oligonucleotide synthesis using ionic liquids as soluble supports. Nucleosides Nucleotides Nucleic Acids 26:1287–1293; c) Donga RA, Chan TH, Damha MJ (2007) Ion-tagged synthesis of an oligoribonucleotide pentamer—the continuing versatility of TBDMS chemistry. Can J Chem 85:274–282Google Scholar
- 20.a) Wada T (2013) Methods for the synthesis of functionalized nucleic acids. International Patent WO 2005/070859 A1, 24 Jan 2013; b) Oka N, Murakami R, Kondo T et al (2013) Stereocontrolled synthesis of dinucleoside phosphorothioates using a fluorous tag. J Fluorine Chem 150:85–91Google Scholar
- 21.a) Pearson WH, Berry DA, Stoy P et al (2005) Fluorous affinity purification of oligonucleotides. J Org Chem 70:7114–7122; b) Berry DA, Pearson WH (2006) Fluorous oligonucleotide reagents and affinity purification of oligonucleotides acids. International Patent WO 2006/081035 A2, 3 Aug 2006; c) Dandapani S (2006) Recent applications of fluorous separation methods in organic and bioorganic chemistry. QSAR Comb Sci 8:681–688Google Scholar
- 22.a) Mishra R, Mishra S, Misra K (2006) Synthesis and application of fluorous-tagged oligonucleotides. Chemistry Lett 35:1184–1185; b) Tripathi S, Misra K, Sanghvi YS (2005) Group for 5′-hydroxyl protection of oligonucleosides. Org Prep Proc Int 37:257–263Google Scholar
- 23.a) Biernat J, Wolter A, Köster H (1983) Purification orientated synthesis of oligodeoxynucleotides in solution. Tetrahedron Lett 24:751–754; b) Wörl R, Köster H (1999) Synthesis of new liquid phase carriers for use in large scale oligonucleotide synthesis in solution. Tetrahedron 55:2941–2956; c) Kungurtsev V, Laakkonen J, Molina AG et al (2013) Solution-phase synthesis of short oligo-2-deoxyribonucleotides by using clustered nucleosides as a soluble support. Eur J Org Chem:6687–6693; d) Kungurtsev V, Virta P, Lönnberg H (2013) Synthesis of short oligodeoxyribonucleotides by phosphotriester chemistry on a precipitative tetrapodal support. Eur J Org Chem 7886:7890Google Scholar
- 25.a) Chiba K, Kin S, Soichiro T et al (2010) Hydrophobic group-linked nucleoside, hydrophobic group-linked nucleoside solution and method of synthesizing hydrophobic group-linked oligonucleotide. Japanese Patent JP 2010-275254, 9 Dec 2010; b) Kim S, Matsumoto M (2013) Oligonucleotide synthesis method using highly dispersible liquid-phase support. International Patent WO 2013/179412 A1, 5 Dec 2013; c) Kim S, Matsumoto M, Chiba K (2013) Liquid-phase RNA synthesis by using alkyl-chain-soluble support. Chem Eur J 19:8615–8620; d) Shoji T, Kim S, Chiba K (2014) Synthesis of conjugated oligonucleotide in solution phase using alkyl-chain-soluble support. Chem Lett 43:1251–1253Google Scholar
- 27.a) Dueymes C, Schönberger A, Adamo I et al (2005) High-yield solution-phase synthesis of di- and trinucleotide blocks assisted by polymer-supported reagents. Org Lett 7:3485–3488; b) Adamo I, Dueymes C, Schönberger A et al (2006) Solution-phase synthesis of phosphorothioate oligonucleotides using a solid-supported acyl chloride with H-phosphonate chemistry. Eur J Org Chem 436–448; c) Adamo I, Dueymes C, Schönberger A et al (2004) Method for preparing oligonucleotides. International Patent WO2004/013154 12 Feb 2004; d) Mohe N, Heinonen P, Sanghvi Y-S et al (2005) A solid supported reagent for internucleoside H-phosphonate linkage formation. Nucleosides Nucleotides Nucleic Acids 24:897–899Google Scholar
- 28.a) Takahashi D (2009) Method for production of peptide. International Patent WO 2009014176, 29 Jan 2009; b) Takahashi D (2009) Method for selective removal of dibenzofulvene derivative. International Patent WO 2009014177 29 Jan 2009; c) Takahashi D (2010) Fluorene compound. International Patent WO 2010104169, 16 Sep 2010; d) Takahashi D (2010) Diphenylmethane compound. International Patent WO 20100249374, 30 Sep 2010; e) Takahashi D (2011) Benzyl compound. International Patent WO 2011078295, 30 Jun 2011; f) Takahashi D, Yano T, Fukui T (2012) Novel diphenylmethyl-derived amide protecting group for efficient liquid-phase peptide synthesis: AJIPHASE. Org Lett 14:4514–4517; g) Takahashi D, Yamamoto T (2012) Development of an efficient liquid-phase peptide synthesis protocol using a novel fluorene-derived anchor support compound with Fmoc chemistry; AJIPHASE®. Tetrahedron Lett 53:1936–1939; h) Takahashi D (2012) Aromatic compound containing specific branch. International Patent WO 2012029794 Mar 8 2012; i) Takahashi D (2012) Method for producing peptide. International Patent WO 2012165545, 6 Dec 2012; j) Takahashi D (2012) Method for producing peptide. International Patent WO 2012165546, 6 Dec 2012; k) Takahashi D (2013) Method for removing Fmoc group. International Patent WO 2013089241, 20 Jun 2013Google Scholar
- 29.a) Hirai K, Katayama S (2012) Method for producing oligonucleotide. International Patent WO 2012157723, 22 Nov 2012; b) Hirai K, Katayama S, Torii T et al (2013) Base-protected oligonucleotide. International Patent WO 2013122236, 22 Aug 2013Google Scholar